ACARIX.ST
Acarix AB (publ) [ACARIX.ST] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ACARIX.ST Stock Summary
In the News
ACARIX.ST Financial details
Company Rating
Sell
Market Cap
201.99M
Income
-77.84M
Revenue
6.24M
Book val./share
0.08
Cash/share
0.05
Dividend
-
Dividend %
-
Employees
20
Optionable
No
Shortable
Yes
Earnings
14 May 2024
P/E
-1.16
Forward P/E
-
PEG
0.27
P/S
22.73
P/B
3.1
P/C
4.9
P/FCF
-1.87
Quick Ratio
0.99
Current Ratio
2.63
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.16
EPS next Y
-
EPS next Q
-
EPS this Y
-42.86%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-33.5%
Revenue last 5Y
27.43%
Revenue Q/Q
-25.37%
EPS Q/Q
-10.21%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-202%
ROE
-186%
ROC
-2.65%
Gross Margin
82%
Oper. Margin
-1214%
Profit Margin
-1227%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.175-0.580486
52W High
-
52W Low
-
RSI
46
Rel Volume
0.16
Avg Volume
4.18M
Volume
666.68K
Perf Week
-9.26%
Perf Month
-7.02%
Perf Quarter
2.3%
Perf Half Y
25%
-
-
-
-
Beta
1.377
-
-
Volatility
0.01%, 0.01%
Prev Close
0.41%
Price
0.245
Change
4.48%
ACARIX.ST Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.05 | 0.02 | 0.02 | 0.02 | 0.01 | |
| Net income per share | -1.23 | -0.39 | -0.3 | -0.28 | -0.16 | |
| Operating cash flow per share | -1.18 | -0.34 | -0.28 | -0.27 | -0.17 | |
| Free cash flow per share | -1.18 | -0.34 | -0.28 | -0.27 | -0.17 | |
| Cash per share | 1.42 | 0.6 | 0.09 | 0.02 | 0.07 | |
| Book value per share | 2.02 | 0.77 | 0.59 | 0.19 | 0.11 | |
| Tangible book value per share | 1.46 | 0.6 | 0.49 | 0.08 | 0.11 | |
| Share holders equity per share | 2.02 | 0.77 | 0.59 | 0.19 | 0.11 | |
| Interest debt per share | 0.02 | 0.01 | 0 | 0 | 0 | |
| Market cap | 48.27M | 126.24M | 148.69M | 79.55M | 90.18M | |
| Enterprise value | -4.66M | 63.54M | 133.4M | 73.18M | 55.03M | |
| P/E ratio | -1.04 | -3.04 | -2.87 | -1.03 | -1.16 | |
| Price to sales ratio | 25.99 | 58.17 | 39.54 | 13.66 | 14.45 | |
| POCF ratio | -1.08 | -3.44 | -3.1 | -1.06 | -1.11 | |
| PFCF ratio | -1.08 | -3.44 | -3.09 | -1.06 | -1.11 | |
| P/B Ratio | 0.63 | 1.54 | 1.48 | 1.53 | 1.74 | |
| PTB ratio | 0.63 | 1.54 | 1.48 | 1.53 | 1.74 | |
| EV to sales | -2.51 | 29.28 | 35.48 | 12.57 | 8.82 | |
| Enterprise value over EBITDA | 0.11 | -1.67 | -2.76 | -0.99 | -0.71 | |
| EV to operating cash flow | 0.1 | -1.73 | -2.78 | -0.98 | -0.68 | |
| EV to free cash flow | 0.1 | -1.73 | -2.78 | -0.98 | -0.68 | |
| Earnings yield | -0.96 | -0.33 | -0.35 | -0.97 | -0.86 | |
| Free cash flow yield | -0.92 | -0.29 | -0.32 | -0.94 | -0.9 | |
| Debt to equity | 0.01 | 0.02 | 0.01 | 0 | 0 | |
| Debt to assets | 0.01 | 0.02 | 0 | 0 | 0 | |
| Net debt to EBITDA | 1.25 | 1.65 | 0.32 | 0.09 | 0.46 | |
| Current ratio | 9.6 | 9.68 | 5.71 | 3.04 | 4.57 | |
| Interest coverage | -829.34 | -796.75 | -728.11 | -469.17 | -180.78 | |
| Income quality | 0.96 | 0.88 | 0.93 | 0.98 | 1.05 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 14.86 | 13.16 | 8.78 | 9.16 | 0 | |
| Research and developement to revenue | 10.92 | 6.67 | 5.72 | 4.77 | 4.57 | |
| Intangibles to total assets | 0.26 | 0.2 | 0.14 | 0.43 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | -0.01 | -0.03 | 0 | |
| Capex to depreciation | 0 | 0 | -0.01 | -0.05 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 7.47 | 2.6 | 2.01 | 1.08 | 0.63 | |
| ROIC | -0.59 | -0.49 | -0.51 | -1.47 | -1.49 | |
| Return on tangible assets | -0.76 | -0.58 | -0.51 | -1.95 | -1.24 | |
| Graham Net | 1.37 | 0.56 | 0.36 | 0.06 | 0.07 | |
| Working capital | 54.29M | 62.88M | 83.91M | 36.02M | 39.3M | |
| Tangible asset value | 55.1M | 63.82M | 84.38M | 22.1M | 51.89M | |
| Net current asset value | 54.22M | 62.31M | 83.67M | 36.02M | 39.3M | |
| Invested capital | 0.01 | 0.02 | 0.01 | 0 | 0 | |
| Average receivables | 1.92M | 2.69M | 41.69M | 58.29M | 21.52M | |
| Average payables | 2.14M | 1.71M | 4.43M | 6.48M | 5.17M | |
| Average inventory | 2.84M | 3.24M | 3.52M | 4.42M | 6.04M | |
| Days sales outstanding | 755.95 | 256.85 | 7.95K | 2.18K | 485.89 | |
| Days payables outstanding | 1.52K | 1.04K | 2.81K | 1.75K | 1.77K | |
| Days of inventory on hand | 2.61K | 2.18K | 1.4K | 1.59K | 2.64K | |
| Receivables turnover | 0.48 | 1.42 | 0.05 | 0.17 | 0.75 | |
| Payables turnover | 0.24 | 0.35 | 0.13 | 0.21 | 0.21 | |
| Inventory turnover | 0.14 | 0.17 | 0.26 | 0.23 | 0.14 | |
| ROE | -0.61 | -0.51 | -0.52 | -1.5 | -1.5 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.01 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.08 | -0.04 | -0.05 | -0.04 | -0.03 | |
| Operating cash flow per share | -0.07 | -0.05 | -0.04 | -0.04 | -0.04 | |
| Free cash flow per share | -0.07 | -0.05 | -0.04 | -0.04 | -0.04 | |
| Cash per share | 0.02 | 0.04 | 0.05 | 0.02 | 0.05 | |
| Book value per share | 0.19 | 0.09 | 0.1 | 0.06 | 0.08 | |
| Tangible book value per share | 0.08 | 0.06 | 0.09 | 0.04 | 0.08 | |
| Share holders equity per share | 0.19 | 0.09 | 0.1 | 0.06 | 0.08 | |
| Interest debt per share | 0 | 0 | 0 | 0 | 0 | |
| Market cap | 79.55M | 208.01M | 278.91M | 112.99M | 121.93M | |
| Enterprise value | 73.18M | 192.19M | 252.71M | 103.79M | 86.78M | |
| P/E ratio | -0.88 | -3.16 | -3.17 | -1.63 | -1.38 | |
| Price to sales ratio | 48.12 | 106.45 | 181.11 | 71.83 | 103.86 | |
| POCF ratio | -4.36 | -10.09 | -13.14 | -6.76 | -5.35 | |
| PFCF ratio | -4.35 | -10.09 | -13.12 | -6.76 | -5.35 | |
| P/B Ratio | 1.53 | 5.65 | 5.92 | 3.89 | 2.35 | |
| PTB ratio | 1.53 | 5.65 | 5.92 | 3.89 | 2.35 | |
| EV to sales | 44.27 | 98.36 | 164.1 | 65.98 | 73.92 | |
| Enterprise value over EBITDA | -3.3 | -12.28 | -11.63 | -6.32 | -3.96 | |
| EV to operating cash flow | -4.01 | -9.33 | -11.9 | -6.21 | -3.81 | |
| EV to free cash flow | -4.01 | -9.33 | -11.89 | -6.21 | -3.81 | |
| Earnings yield | -0.28 | -0.08 | -0.08 | -0.15 | -0.18 | |
| Free cash flow yield | -0.23 | -0.1 | -0.08 | -0.15 | -0.19 | |
| Debt to equity | 0 | 0 | 0 | 0 | 0 | |
| Debt to assets | 0 | 0 | 0 | 0 | 0 | |
| Net debt to EBITDA | 0.29 | 1.01 | 1.21 | 0.56 | 1.6 | |
| Current ratio | 3.04 | 3.27 | 3.43 | 2.63 | 4.57 | |
| Interest coverage | 63.7 | -234.77 | -148.95 | -220.85 | -165.41 | |
| Income quality | 0.81 | 1.25 | 0.96 | 0.97 | 1.03 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 8.65 | 6.68 | 0 | 7.71 | 0 | |
| Research and developement to revenue | 5.83 | 2.59 | 5.43 | 4.07 | 6.61 | |
| Intangibles to total assets | 0.43 | 0.31 | 0.07 | 0.34 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | -0.01 | 0 | -0.02 | 0.01 | 0 | |
| Capex to depreciation | -0.01 | 0 | -0.16 | 0.02 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 0.58 | 0.29 | 0.32 | 0.23 | 0.25 | |
| ROIC | -0.43 | -0.44 | -0.46 | -0.59 | -0.42 | |
| Return on tangible assets | -0.57 | -0.51 | -0.39 | -0.68 | -0.35 | |
| Graham Net | 0.06 | 0.04 | 0.05 | 0.02 | 0.05 | |
| Working capital | 36.02M | 21.75M | 32.03M | 15.34M | 39.3M | |
| Tangible asset value | 22.1M | 22.6M | 43M | 15.88M | 51.89M | |
| Net current asset value | 36.02M | 21.75M | 32.03M | 15.34M | 39.3M | |
| Invested capital | 0 | 0 | 0 | 0 | 0 | |
| Average receivables | 20.29M | 22.02M | 10.85M | 10.26M | 8.22M | |
| Average payables | 3.19M | 3.3M | 2M | 3.17M | 3.89M | |
| Average inventory | 5.22M | 5.62M | 6.27M | 6.94M | 7.09M | |
| Days sales outstanding | 1.89K | 429.5 | 723.33 | 465.85 | 636.9 | |
| Days payables outstanding | 1.6K | 289.21 | 1.13K | 1.02K | 2.83K | |
| Days of inventory on hand | 1.46K | 2.02K | 2.36K | 2.35K | 4.22K | |
| Receivables turnover | 0.05 | 0.21 | 0.12 | 0.19 | 0.14 | |
| Payables turnover | 0.06 | 0.31 | 0.08 | 0.09 | 0.03 | |
| Inventory turnover | 0.06 | 0.04 | 0.04 | 0.04 | 0.02 | |
| ROE | -0.44 | -0.45 | -0.47 | -0.59 | -0.43 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
ACARIX.ST Frequently Asked Questions
What is Acarix AB (publ) stock symbol ?
Acarix AB (publ) is a SE stock and trading under the symbol ACARIX.ST
What is Acarix AB (publ) stock quote today ?
Acarix AB (publ) stock price is $0.245 today.
Is Acarix AB (publ) stock public?
Yes, Acarix AB (publ) is a publicly traded company.
Company Profile
- Volume Average 4.18M
- Market Capitalization 201.99M
- Employee 20
- CEO Mr. Aamir Mahmood
- Headquarters Malmö,SE
- IPO Date 2016-12-19
-
Website
https://www.acarix.com 
Acarix AB (publ), a medical technology company, develops and commercializes diagnostic tests for cardiovascular diseases in Germany, Sweden, the Middle East, Switzerland, Austria, and internationally. The company offers CADScor System, a non-invasive and ultra-sensitive analytical device for the diagnosis of coronary artery disease. Acarix AB (publ) was founded in 2009 and is headquartered in Malmö, Sweden.
